Press Release

Novo Nordisk A/S and BD are dominating the Latin America Pen Needles Market in 2018

Latin America Pen Needles Market is expected to grow at a substantial CAGR in the forecast period of 2019 to 2026. The years considered for study are as mentioned below.

Access Full Report at

Latin America pen needles market is an upcoming market which includes key players and local players. The market is growing to the favourable market scenario. The market has a prominent growth in upcoming years due to increasing prevalence of diabetes and geriatric population.

Novo Nordisk A/S dominated the pen needles market. The other key players existing in the market includes are BD, B. Braun Melsungen AG, HTL-STREFA, MedExel Co., Ltd., Owen Mumford Ltd others.

Novo Nordisk A/S:

Novo Nordisk A/S headquartered in Bagsvaerd, Denmark was founded in 1989. The company focuses on developing and providing innovative diabetes care products. The company is providing diabetes care, obesity, disease experience expert panels, hemophilia, growth disorders, hormone replacement therapy. The market focus products lie under Diabetes care.  The company deals into diabetes and obesity, biopharmaceuticals business categories. The market focus products lie under Diabetes and obesity business segment. The company is continuously engaged in developing the pen needles.

It has its global presence through its subsidiaries Novo Nordisk Pharma Argentina S.A., (Argentina), Novo Nordisk Producao Farmacêutica do Brasil Ltda. (Brazil), Novo Nordisk Farmaceutica do Brasil Ltda. (Brazil), Novo Nordisk Farmaceutica Limitada (Chile), Novo Nordisk Colombia SAS (Colombia) among others.

It has its global networks through direct sales representatives and distributors in North America, Europe, Latin America, Middle East, Asia-Pacific and Africa.


BD headquartered in New Jersey, U.S. was founded in 1897. The company focuses on the development, manufacturing and sales of medical supplies, devices, laboratory equipment and diagnostic products. The company mainly manages their operation in Medical, Life Sciences, and Interventional. The market focus category lies under Medical. The company is providing anesthesia delivery, biosciences, biosurgery, cervical cancer screening, diabetes care, drug delivery systems, gastrointestinal care, hazardous drug safety, hernia repair and fixation, Home care, Infection prevention, Infusion therapy, Interventional specialties, Lab automation, Medication and supply management, Microbiology solutions, Molecular diagnostics, Patient monitoring and temperature management, Prostate health, Respiratory care, Sharps disposal solutions, Single cell multiomics, Software solutions, Specimen collection, Surgical instruments, Syringes and needles, Urology and kidney health, Vascular access, Vascular surgery and Wound care. The market focused category lie under Diabetes care categories.  The company is continuously engaged in developing the pen needles.

It has its global networks through subsidiaries in Eastern Europe, the Middle East, Africa, Latin America, and Asia-Pacific. Its subsidiaries are CareFusion (U.S.), C. R. Bard (U.S), Accuri Cytometers Inc. (U.S.), TVA Medical, Inc.  (U.S.), Becton Dickinson AcuteCare Inc.  (West Africa), TriPath Imaging, Inc. (U.S.).

Client Testimonials